Air & Water Borne Diseases
Open Access

Measles control; Vaccination; Therapy; Treatment; Epidemiological impact; Measles transmission dynamics

Introduction

Measles, a highly contagious viral disease, has been a significant public health concern for decades, causing immense suffering and mortality, especially among children. However, the past century has witnessed remarkable advancements in our understanding of measles transmission dynamics and the development of effective tools for its control. Vaccination, in particular, has played a pivotal role in reducing the global burden of measles. But in recent years, there has been growing recognition that a comprehensive strategy involving not just vaccination but also therapy and treatment can have a more profound impact on controlling measles and minimizing its adverse epidemiological consequences. In this article, we explore the epidemiological impact of combining vaccination, therapy, and treatment in measles control [1,2].

Measles as a highly contagious and serious viral disease has been known for centuries. Measles is caused by paramyxovirus, an RNA virus classified under the Morbillivirus genus of the Paramyxoviridae family. Initially beginning with flu-like symptoms which appear 7 to 14 days after contact with the virus, measles presents with Koplik spots inside the mouth and rashes which appear 2 to 5 days after the first symptoms, starting on the head and face and spreading through the body. Measles can be dangerous, especially for babies, young children under five, and adults older than 20 years of age. Measles is also infectious for a few days after rash onset, commonly accompanyed by high fever, red and watery eyes, cough, and runny nose [3]. About one-third of reported measles cases have one or more complications, ranging from common complications such as ear infections (otitis media) and diarrhea to serious complications such as pneumonia and acute encephalitis.

Measles transmission dynamics

Measles is caused by the measles virus and is transmitted from person to person through respiratory droplets. The virus is highly contagious, with an R₀ (the basic reproductive number) estimated to be between 12 and 18. This means that a single case can infect up to 18 other individuals if none are immune or vaccinated. Measles can lead to severe complications, including pneumonia and encephalitis, and is particularly dangerous for vulnerable populations, such as infants and individuals with compromised immune systems [4].

The role of vaccination

Vaccination has been the cornerstone of measles control efforts.

The measles, mumps, and rubella (MMR) vaccine is highly effective, providing long-lasting immunity. High vaccine coverage rates have significantly reduced measles incidence in many parts of the world. The World Health Organization (WHO) established a goal to eliminate measles in at least five of its six regions by 2020, and vaccination was central to this initiative [5].

However, despite the successes of vaccination programs, measles has not been eradicated globally. Measles cases and outbreaks continue to occur in countries with suboptimal vaccine coverage rates or where vaccine hesitancy is on the rise.

The role of therapy and treatment

Therapy and treatment are often overlooked in measles control, but they can have a significant impact, especially during outbreaks. Therapy may include the use of antiviral drugs, while treatment focuses on supportive care to manage symptoms and complications. Timely intervention with therapy and treatment can reduce the severity of measles, shorten the duration of illness, and decrease the risk of complications [6,7].

Combining Vaccination, Therapy, and Treatment

The synergistic approach of combining vaccination, therapy, and treatment can yield substantial benefits in measles control:

• Reduced transmission: Vaccination prevents infection, therapy reduces the viral load in infected individuals, and treatment helps manage complications. Together, these measures reduce the pool of infectious individuals and limit transmission.

• Herd immunity: Achieving high vaccination coverage creates herd immunity, which indirectly protects those who cannot be vaccinated, such as infants, pregnant women, and individuals with contraindications to vaccination.

• Outbreak management: In the event of an outbreak, therapy and treatment can be crucial in mitigating the severity and spread of the disease, thereby preventing a large-scale epidemic.

• Reduced healthcare burden: Comprehensive measles control can reduce the strain on healthcare systems, ensuring that resources are available for other medical needs [8].

Discussion

Firstly, measles transmission dynamics underscore the high contagiousness of the virus, emphasizing the importance of robust control strategies. Vaccination, as the most effective preventive measure, plays a central role in reducing measles incidence. Achieving high vaccine coverage rates creates herd immunity, which indirectly protects those who are unable to be vaccinated, thereby contributing to the overall decline in measles transmission [9].

However, as evidenced by ongoing outbreaks in areas with suboptimal vaccine coverage, vaccination alone may not be sufficient to achieve complete measles control. This is where the integration of therapy and treatment becomes crucial. Therapy, including the use of antiviral drugs, can reduce the viral load in infected individuals, making them less contagious and shortening the duration of illness. Treatment, through supportive care, can manage complications and reduce the severity of the disease. In the context of an outbreak, early intervention with therapy and treatment can be particularly valuable, helping to prevent large-scale epidemics [10].

A significant advantage of a comprehensive approach that combines vaccination, therapy, and treatment is the potential to reduce the healthcare burden. Measles can overwhelm healthcare systems during outbreaks, and treatment can mitigate this strain by ensuring resources are available for other medical needs. Moreover, the reduction in the severity and spread of the disease leads to lower healthcare costs and less disruption to healthcare services.

Conclusion

In conclusion, the epidemiological impact of combining vaccination, therapy, and treatment in measles control cannot be understated. While vaccination remains the cornerstone of measles control efforts, it is essential to recognize the value of a holistic strategy that considers all aspects of control. This approach offers a more comprehensive solution to the complex challenge of measles control, one that can significantly reduce transmission, minimize complications, and improve overall epidemiological outcomes.

The synergistic effect of these measures creates a stronger defense against measles, ultimately contributing to the goal of global measles eradication. To achieve this objective, public health efforts should continue to emphasize the importance of a comprehensive strategy that integrates vaccination, therapy, and treatment. Furthermore, promoting awareness and education on the significance of vaccination and the availability of therapy and treatment is vital in reducing vaccine hesitancy and ensuring the well-being of all populations, especially those most vulnerable to the effects of measles. By embracing this multifaceted approach, we can move closer to a world where measles is no longer a global health concern.

Acknowledgement

None

Conflict of Interest

None

References

1. Ferrari M.J, Grais RF, Bharti N, Conlan AJK, Bjornstad ON, et al. (2008) The dynamics of measles in sub-Saharan Africa.Nature 451: 679- 684

Indexed at, Google Scholar, Crossref

2. Bharti N, Djibo A, Ferrari MJ, Grais RF, Tatem AJ, et al. (2010) Measles hotspots and epidemiological connectivity.Epidemiol Infect 138: 1308–1316.

Indexed at, Google Scholar, Crossref

3. Nic Lochlainn L, Mandal S, de Sousa R, Paranthaman K, van Binnendijk R, et al. (2016) A unique measles B3 cluster in the United Kingdom and the Netherlands linked to air travel and transit at a large international airport, February to April 2014.Euro Surveill 21: 30177

Indexed at, Google Scholar, Crossref

4. Lee AD, Clemmons NS, Patel M, Gastañaduy PA (2019) International importations of measles virus into the United States during the postelimination era, 2001–2016.J Infect Dis 219: 1616–1623.

Indexed at, Google Scholar, Crossref

5. Bharti N, Tatem AJ, Ferrari MJ, Grais RF, Djibo A, et al. (2011) Explaining seasonal fluctuations of measles in Niger using nighttime lights imagery.Science 334: 1424–1427.

Indexed at, Google Scholar, Crossref

6. Glasser JW, Feng Z, Omer SB, Smith PJ, Rodewald LE (2016) The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study.Lancet Infect Dis 16: 599–605.

Indexed at, Google Scholar, Crossref

7. Funk S, Knapp JK, Lebo E, Reef SE, Dabbagh AJ, et al. (2019) Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.BMC Med 17: 180.

Indexed at, Google Scholar, Crossref

8. Wesolowski A, Metcalf CJE, Eagle N, Kombich J, Grenfell BT, et al. (2015) Quantifying seasonal population fluxes driving rubella transmission dynamics using mobile phone data.Proc Natl Acad Sci USA 112: 11114–11119.

Indexed at, Google Scholar, Crossref

9. Wesolowski A, Erbach-Schoenberg E.zu, Tatem AJ, Lourenço C, Viboud C, et al. (2017) Multinational patterns of seasonal asymmetry in human movement influence infectious disease dynamics.Nat Commun 8: 2069.

Indexed at, Google Scholar, Crossref

10. McKee A, Ferrari MJ, Shea K (2018) Correlation between measles vaccine doses: implications for the maintenance of elimination.Epidemiol Infect146: 468–475.

Indexed at, Google Scholar, Crossref